Search results
Results From The WOW.Com Content Network
Epiploic appendagitis (EA) is an uncommon, benign, self-limiting inflammatory process of the epiploic appendices. Other, older terms for the process include appendicitis epiploica and appendagitis , but these terms are used less now in order to avoid confusion with acute appendicitis .
The dominion of right-sided abdominal pain in omental infarction has been attributed to right segmental infarction as a result of the tenuous blood vessels in this part of the omentum as well as its longer size and higher mobility in comparison to the left side which subjects it to torsion. Obesity is a known risk factor for omental infarction.
The epiploic appendices (or appendices epiploicae, or epiploic appendages, or appendix epiploica, or omental appendices) are small pouches of the peritoneum filled with fat and situated along the colon, but are absent in the rectum. They are chiefly appended to the transverse and sigmoid parts of the colon, however, their function is unknown.
The common anatomical term "epiploic" derives from "epiploon", from the Greek epipleein, meaning to float or sail on, since the greater omentum appears to float on the surface of the intestines. It is the first structure observed when the abdominal cavity is opened anteriorly (from the front).
Appendicitis is inflammation of the appendix. [2] Symptoms commonly include right lower abdominal pain, nausea, vomiting, fever and decreased appetite. [2] However, approximately 40% of people do not have these typical symptoms. [2]
Radwah Oda was diagnosed with colon cancer at 30. She shares five symptoms she dismissed, including narrow stools, blood in the stool, pain and fatigue.
In human anatomy, the omental foramen (epiploic foramen, foramen of Winslow after the anatomist Jacob B. Winslow, or uncommonly aditus; Latin: Foramen epiploicum) is the passage of communication, or foramen, between the greater sac, and the lesser sac of the peritoneal cavity.
A new review reports that nine people taking semaglutide and tirzepatide — the active ingredient in GLP-1 medications — experienced vision issues, including three potentially blinding eye ...